ID   PDIS-2
AC   CVCL_RN07
SY   HEK-293T/hPDPN-knockout; HEK-293T/hPDPN-KO
DR   Wikidata; Q54946846
RX   PubMed=26937552;
RX   PubMed=27031228;
RX   PubMed=27328060;
RX   PubMed=27564251;
RX   PubMed=28101903;
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 29602; PDPN.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5.
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [Note=tsA].
CC   Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0063 ! HEK293T
SX   Female
AG   Fetus
CA   Transformed cell line
DT   Created: 05-03-18; Last updated: 30-01-24; Version: 8
//
RX   PubMed=26937552; DOI=10.1089/mab.2015.0077;
RA   Kato Y., Ogasawara S., Oki H., Honma R., Takagi M., Fujii Y.,
RA   Nakamura T., Saidoh N., Kanno H., Umetsu M., Kamata S., Kubo H.,
RA   Yamada M., Sawa Y., Morita K.-i., Harada H., Suzuki H., Kaneko M.K.;
RT   "Novel monoclonal antibody LpMab-17 developed by CasMab technology
RT   distinguishes human podoplanin from monkey podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 35:109-116(2016).
//
RX   PubMed=27031228; DOI=10.1371/journal.pone.0152912;
RA   Kato Y., Ogasawara S., Oki H., Goichberg P., Honma R., Fujii Y.,
RA   Kaneko M.K.;
RT   "LpMab-12 established by CasMab technology specifically detects
RT   sialylated O-glycan on Thr52 of platelet aggregation-stimulating
RT   domain of human podoplanin.";
RL   PLoS ONE 11:E0152912-E0152912(2016).
//
RX   PubMed=27328060; DOI=10.1089/mab.2016.0006;
RA   Ogasawara S., Kaneko M.K., Honma R., Oki H., Fujii Y., Takagi M.,
RA   Suzuki H., Kato Y.;
RT   "Establishment of mouse monoclonal antibody LpMab-13 against human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 35:155-162(2016).
//
RX   PubMed=27564251; DOI=10.1089/mab.2016.0031;
RA   Ogasawara S., Kaneko M.K., Kato Y.;
RT   "LpMab-19 recognizes sialylated O-Glycan on Thr76 of human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 35:245-253(2016).
//
RX   PubMed=28101903; DOI=10.1002/cam4.954;
RA   Kaneko M.K., Nakamura T., Honma R., Ogasawara S., Fujii Y., Abe S.,
RA   Takagi M., Harada H., Suzuki H., Nishioka Y., Kato Y.;
RT   "Development and characterization of anti-glycopeptide monoclonal
RT   antibodies against human podoplanin, using glycan-deficient cell lines
RT   generated by CRISPR/Cas9 and TALEN.";
RL   Cancer Med. 6:382-396(2017).
//